The role of PCA 3 as a prognostic factor in patients with castration-resistant prostate cancer (CRPC) treated with Docetaxel.

Authors
Bourdoumis, A
Chrisofos, M
Stasinou, T
Christopoulos, Panagiotis
Mourmouris, P
Kostakopoulos, A
Deliveliotis, C
Affiliation
Department of Urology, Torbay Hospital, South Devon Healthcare NHS Foundation Trust, Torquay
Issue Date
2015-05

Metadata
Show full item record
Abstract
To investigate potential fluctuations in prostate cancer antigen 3 (PCA 3) scores in castration-resistant prostate cancer (CRPC) patients treated with docetaxel and investigate the assay as a potential prognostic factor.
Citation
The role of PCA 3 as a prognostic factor in patients with castration-resistant prostate cancer (CRPC) treated with Docetaxel. 2015, 35 (5):3075-9 Anticancer Res
Journal
Anticancer Research
URI
http://hdl.handle.net/10541/558714
PubMed ID
25964598
Type
Article
Language
en
ISSN
1791-7530
Collections